Tenofovir alafenamide Side Effects
Commonly reported side effects of tenofovir alafenamide include: abdominal pain, depression, nausea, vomiting, and vesicobullous reaction. Other side effects include: pneumonia, and decreased bone mineral density. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to tenofovir alafenamide: oral tablet
Along with its needed effects, tenofovir alafenamide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking tenofovir alafenamide:Incidence not known
- Abdominal or stomach discomfort
- bloody urine
- dark urine
- decreased appetite
- decreased frequency or amount of urine
- fast, shallow breathing
- general feeling of discomfort
- increased blood pressure
- increased thirst
- light-colored stools
- loss of appetite
- lower back or side pain
- muscle pain or cramping
- nausea and vomiting
- right upper abdominal or stomach pain and fullness
- swelling of the face, fingers, or lower legs
- troubled breathing
- unusual tiredness or weakness
- weight gain
- yellow eyes and skin
Some side effects of tenofovir alafenamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
For Healthcare Professionals
Applies to tenofovir alafenamide: oral powder, oral tablet
During controlled clinical trials, the most common side effects reported with tenofovir disoproxil fumarate (DF) in HIV-1-infected patients included rash, diarrhea, headache, pain, depression, asthenia, and nausea. The most common side effects associated with this drug in combination with other antiretrovirals have included mild to moderate gastrointestinal events (e.g., nausea, diarrhea, vomiting, and flatulence) in therapy-experienced patients and mild to moderate gastrointestinal events and dizziness in therapy-naive patients. About 1% of patients in clinical trials discontinued therapy due to gastrointestinal side effects.
During controlled clinical trials, the most common side effects reported with tenofovir DF in patients with chronic hepatitis B virus (HBV) infection and compensated liver disease included nausea, abdominal pain, diarrhea, headache, dizziness, fatigue, nasopharyngitis, back pain, and skin rash. In patients with chronic HBV and decompensated liver disease, the most common side effects reported during a controlled trial included abdominal pain, nausea, insomnia, pruritus, vomiting, dizziness, and pyrexia.[Ref]
Abdominal pain (any severity: 22%), nausea (any severity: 20%), and vomiting (any severity: 13%) have been in patients with chronic HBV and decompensated liver disease (n=45).
Pancreatitis, abdominal pain, and elevated amylase have also been reported during postmarketing experience.[Ref]
Very common (10% or more): Abdominal pain (up to 22%), nausea (up to 20%), diarrhea (up to 16%), vomiting (up to 13%)
Common (1% to 10%): Elevated serum amylase, flatulence, dyspepsia, abdominal distension, upper abdominal pain
Uncommon (0.1% to 1%): Pancreatitis, elevated serum lipase[Ref]
Serum phosphorus less than 2 mg/dL was reported in a patient with chronic HBV and decompensated liver disease.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.
Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.
Lactic acidosis, hypokalemia, and hypophosphatemia have also been reported during postmarketing experience.[Ref]
Very common (10% or more): Elevated fasting cholesterol (up to 22%), elevated triglycerides (up to 11%), hypophosphatemia
Common (1% to 10%): Elevated fasting triglycerides, anorexia, elevated serum glucose/hyperglycemia, elevated alkaline phosphatase
Uncommon (0.1% to 1%): Hypokalemia
Rare (0.01% to 0.1%): Lactic acidosis
Frequency not reported: Serum phosphorus less than 2 mg/dL, higher 1,25 vitamin D levels
-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), increased blood lipid levels, increased glucose levels[Ref]
Very common (10% or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, exfoliative rash, generalized rash, macular rash, pruritic rash, vesicular rash; up to 18%), pruritus (up to 16%)
Common (1% to 10%): Sweating
Uncommon (0.1% to 1%): Lipodystrophy
Rare (0.01% to 0.1%): Angioedema
Frequency not reported: Lichenoid drug eruption with eosinophilia[Ref]
Pruritus (any severity: 16%) has been reported in patients with chronic HBV and decompensated liver disease (n=45).
Rash has also been reported during postmarketing experience.[Ref]
Insomnia (any severity: 18%) was reported in patients with chronic HBV and decompensated liver disease (n=45).
Very common (10% or more): Insomnia (up to 18%), depression (up to 11%)
Common (1% to 10%): Anxiety, abnormal dreams
Very common (10% or more): Headache (up to 14%), dizziness (up to 13%)
Common (1% to 10%): Peripheral neuropathy (including peripheral neuritis and neuropathy)
Frequency not reported: Somnolence, paresthesia[Ref]
Dizziness (any severity: 13%) was reported in patients with chronic HBV and decompensated liver disease (n=45).[Ref]
Pyrexia (any severity: 11%) was reported in patients with chronic HBV and decompensated liver disease (n=45).
Asthenia has also been reported during postmarketing experience.[Ref]
Very common (10% or more): Pain (up to 13%), pyrexia/fever (up to 11%), asthenia (up to 11%)
Common (1% to 10%): Fatigue, weight loss, chest pain, procedural pain
-Frequency not reported: Increased weight[Ref]
Very common (10% or more): Elevated creatine kinase (up to 12%)
Common (1% to 10%): Arthralgia, myalgia, back pain
Uncommon (0.1% to 1%): Rhabdomyolysis, muscular weakness
Rare (less than 0.1%): Myopathy
Frequency not reported: Decreased bone mineral density, increased biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C telopeptide, urinary N telopeptide), clinically relevant fractures (excluding fingers and toes), bone abnormalities (infrequently contributing to fractures), osteonecrosis
Postmarketing reports: Osteomalacia (manifested as bone pain and which may contribute to fractures)[Ref]
Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.
Rhabdomyolysis, muscular weakness, and myopathy have also been reported during postmarketing experience.[Ref]
Death due to progression of liver disease has been reported in 4% of patients with chronic HBV and decompensated liver disease (n=45).
On-treatment ALT or hepatic flares have been reported in patients with chronic HBV. In general, ALT flares occurred within the first 4 to 8 weeks of therapy, accompanied by decreases in HBV-DNA levels, and resolved within 4 to 8 weeks without changes to therapy.
Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of this drug.
Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.
Hepatic steatosis and hepatitis have also been reported during postmarketing experience.[Ref]
Common (1% to 10%): Elevated transaminases, elevated ALT, elevated AST, death due to progression of liver disease
Rare (0.01% to 0.1%): Hepatic steatosis, hepatitis
Frequency not reported: On-treatment ALT or hepatic flares, lactic acidosis/severe hepatomegaly with steatosis (including fatal cases), severe acute exacerbations of hepatitis
Postmarketing reports: Elevated liver enzymes (primarily AST, ALT, gamma glutamyltransferase)[Ref]
A confirmed increase in serum creatinine of 0.5 mg/dL was reported in 9% of patients with chronic HBV and decompensated liver disease (n=45); however, since tenofovir and decompensated liver disease may have an impact on renal function, the contribution of tenofovir to renal impairment in these patients is difficult to ascertain.
Proximal renal tubulopathy generally resolved or improved after this drug was stopped; however, decreased CrCl did not completely resolve in some patients after stopping tenofovir DF. Rhabdomyolysis, osteomalacia, bone abnormalities (infrequently contributing to fractures), hypokalemia, muscular weakness, myopathy, and hypophosphatemia may occur as a result of proximal renal tubulopathy.
Renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, nephrogenic diabetes insipidus, and acute tubular necrosis have also been reported during postmarketing experience.[Ref]
Common (1% to 10%): Increased creatinine
Uncommon (0.1% to 1%): Proximal renal tubulopathy (including Fanconi syndrome)
Rare (0.01% to 0.1%): Acute renal failure, renal failure, acute tubular necrosis, nephrogenic diabetes insipidus
Frequency not reported: New onset or worsening renal impairment, nephritis, decreased CrCl
Postmarketing reports: Renal insufficiency, interstitial nephritis (including acute cases)[Ref]
Common (1% to 10%): Decreased neutrophils[Ref]
Postmarketing reports: Allergic reaction (including angioedema)[Ref]
Frequency not reported: Higher serum parathyroid hormone levels
1. "Product Information. Viread (tenofovir)." Gilead Sciences, Foster City, CA.
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. Paxton LA, Hope T, Jaffe HW "Pre-exposure prophylaxis for HIV infection: what if it works?" Lancet 370 (2007): 89-93
4. AIDSinfo. NIH. National Institutes of Health "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf." ([2016 Mar 1]):
5. Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF "Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment." Clin Pharmacokinet 45 (2006): 1115-24
6. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf." (4/8/2015):
7. Blum MR, Chittick GE, Begley JA, Zong J "Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers." J Clin Pharmacol 47 (2007): 751-9
8. Munoz de Benito RM, Arribas Lopez JR "Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone." Expert Rev Anti Infect Ther 4 (2006): 523-535
9. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33
10. Warnke D, Barreto J, Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9
11. Baeten JM, Donnell D, Ndase P, et al. "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women." N Engl J Med 367 (2012): 399-410
12. "Drugs for HIV infection." Med Lett Drugs Ther 43 (2001): 103-8
13. Blaas S, Schneidewind A, Gluck T, Salzberger B "Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases." AIDS 20 (2006): 1786-7
14. Fux CA, Christen A, Zgraggen S, Mohaupt MG, Furrer H "Effect of tenofovir on renal glomerular and tubular function." AIDS 21 (2007): 1483-5
15. Shepp DH, Curtis S, Rooney JF "Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate." AIDS 21 (2007): 1479-81
16. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
17. Cirino CM, Kan VL "Hypokalemia in HIV patients on tenofovir." AIDS 20 (2006): 1671-3
18. Izzedine H, Launay-Vacher V, Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17
19. Woolley IJ, Veitch AJ, Harangozo CS, Moyle M, Korman TM "Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient." AIDS 18 (2004): 1857-8
20. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88
21. "A once-daily combination tablet (Atripla) for HIV." Med Lett Drugs Ther 48 (2006): 78-9
22. Frampton JE, Croom KF "Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate: triple combination tablet." Drugs 66 (2006): 1501-12
23. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22
24. Callens S, De Schacht C, Huyst V, Colebunders R "Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment." J Infect 47 (2003): 188-9
25. Agarwala R, Mohan S, Herlitz LC, Cheng JT "The case: 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Tenofovir toxicity." Kidney Int 77 (2010): 475-6
26. Hammer SM, Saag MS, Schechter M, et al. "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA 296 (2006): 827-43
27. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis 42 (2006): 1488-95
28. Izzedine H, Launay-Vacher V, Deray G "Renal tubular transporters and antiviral drugs: an update." AIDS 19 (2005): 455-62
29. Szczech LA "Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context." J Infect Dis 197 (2008): 7-9
30. Izzedine H, Hulot JS, Villard E, et al. "Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy." J Infect Dis 194 (2006): 1481-91
31. Anderson PL "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother 38 (2004): 1969-70
32. Perazella MA "Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity." Am J Med Sci 325 (2003): 349-62
33. Kelly MD, Gibson A, Bartlett H, Rowling D, Patten J "Tenofovir associated proteinuria." AIDS 27 (2012): 479-81
Some side effects of tenofovir alafenamide may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
More about tenofovir alafenamide
- Side Effects
- During Pregnancy
- Drug Interactions
- Support Group
- Pricing & Coupons
- 0 Reviews – Add your own review/rating
- Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)
Other brands: Vemlidy
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.